A healthtech startup testing a single web application or small network before Series A typically pays $5,000 to $15,000 for a HIPAA-focused penetration test, rising to $15,000 to $35,000 when the scope expands to web app, API, and cloud infrastructure together, according to Startup Defense's cost breakdown. That range sits well below the $15,000–$40,000 floor for a small healthcare environment overall, because most pre-Series-A companies haven't yet built the multi-app, multi-network footprint that pushes healthcare pentest pricing into six figures, per Accountable HQ's healthcare pricing analysis. The number that matters most isn't the headline price — it's what's actually being tested, and whether it's a real manual engagement or an automated scan wearing a pentest's name. Founders who get this wrong either overpay for scope they don't need yet or underpay for a report that won't hold up to a risk analysis or an investor's diligence request.
Table of Contents
- What drives the price up or down
- Where pentesting fits in a full compliance budget
- Does HIPAA actually require a penetration test?
- How to avoid paying for the wrong thing
- Will investors actually ask for this before Series A?
- Frequently Asked Questions
What drives the price up or down
Penetration testing cost scales with the size and complexity of what's being tested, not with company headcount or funding stage directly. A small environment — one external perimeter plus one or two applications — runs $15,000 to $40,000, while a mid-size system with external and internal networks, multiple apps, and wireless infrastructure runs $40,000 to $120,000, according to Accountable HQ. Large, complex networks — multi-hospital systems, hybrid cloud, or connected medical devices — run $120,000 to $300,000 or more.
Most pre-Series-A healthtech companies fall well under that ceiling because they're running one product, not a hospital network. A single web application with 25 to 50 key functions prices at $10,000 to $35,000 on its own, and API testing — including FHIR or SMART-on-FHIR endpoints common in health data integrations — runs $8,000 to $30,000, per the same Accountable HQ breakdown. That component-level pricing is why the Startup Defense figures land lower: a pre-Series-A company testing one app or a small network pays $5,000 to $15,000, and a combined web app, API, and cloud scope commonly runs $15,000 to $35,000 (Startup Defense). The gap between that and Accountable HQ's healthcare-specific numbers reflects scope: a single-component test versus a fuller assessment that explicitly accounts for HIPAA's technical evaluation requirements.
Where pentesting fits in a full compliance budget
A pentest is one line item, not the whole bill. For a roughly 10-person telehealth startup with limited PHI exposure, the full initial HIPAA compliance program — risk assessment, policies, and technical testing together — runs $25,000 to $70,000, within which the penetration test itself is $6,000 to $20,000, separate from the gap assessment, according to Accountable HQ's ROI analysis. Zooming out to total year-one compliance spend, a pre-seed company with one to ten staff should budget $8,000 to $25,000, with $3,000 to $10,000 per year ongoing after that.
A seed-stage company with 11 to 50 staff should expect $25,000 to $85,000 in year one, per Accountable HQ's startup budgeting guide. A founder budgeting for "HIPAA compliance" as if it were a single pentest invoice will underestimate total spend significantly. Retesting after remediation is a further cost most first-time budgets miss. Confirming that fixes actually closed the identified vulnerabilities commonly bills at 10% to 30% of the original engagement, or roughly $2,000 to $5,000 for a startup-scale test, per Startup Defense and DeepStrike.
Does HIPAA actually require a penetration test?
Not by name. HIPAA's Security Rule doesn't use the term "penetration testing" anywhere in its text. The obligation comes indirectly, from the required risk analysis and the periodic technical evaluation duty at 45 CFR §164.308(a)(8) — a pentest is one way to satisfy that duty, but having one doesn't by itself prove compliance, according to Accountable HQ's explainer on the Security Rule.
HIPAA also sets no fixed testing schedule. Vendor guidance has converged on an informal industry norm: test annually, and retest after any significant system change, for business associates handling electronic protected health information, per Accountable HQ's guidance for business associates. A startup launching a new EHR integration or a major platform rebuild should treat that as a retest trigger, not wait for the calendar year to turn over. This distinction matters for budgeting: a company can satisfy its technical evaluation duty through a well-documented risk analysis plus a targeted pentest, without needing to commission the largest, most expensive assessment available.
How to avoid paying for the wrong thing
The biggest pricing trap is mistaking an automated scan for a manual penetration test. A quoted price of $2,000 to $4,000 for a "pentest" is very likely an automated vulnerability scan, not genuine manual testing, a distinction flagged across multiple 2026 pricing guides, per DeepStrike.
Accountable HQ prices an automated scan at $3,000 to $15,000 and is explicit that it is not a substitute for a manual test, because HIPAA's risk-analysis duty expects a substantive technical evaluation, not a scan report (Accountable HQ). Before requesting quotes, founders should be able to answer: Getting scope right the first time avoids the common failure mode: a startup pays for a narrow automated scan, discovers during diligence or an actual incident that it doesn't satisfy the technical evaluation requirement, and has to commission a second, proper test under time pressure.
- What's in scope — one app, or app plus API plus cloud infrastructure plus network?
- Does the quote include manual exploitation attempts, or only automated tooling?
- Is retesting after remediation included, or billed separately?
- Does the vendor's report map findings to HIPAA's risk analysis requirements, or is it a generic vulnerability list?
Will investors actually ask for this before Series A?
Most Series A investors do not formally require a SOC 2 report as a funding condition for a healthtech startup. A penetration test report paired with a credible remediation roadmap is generally treated as sufficient at that stage, with SOC 2 becoming a more common ask by Series B, according to Cybersecify's analysis of investor security expectations.
That makes the pentest the more immediately relevant investment for a pre-Series-A healthtech company: it's cheaper than a SOC 2 audit, it directly supports the HIPAA risk analysis obligation, and it's the artifact most likely to actually get requested during diligence. A founder prioritizing budget before a raise gets more practical value from a properly scoped manual pentest with a remediation plan than from starting SOC 2 preparation early.
Frequently Asked Questions
Is a $3,000 penetration test quote a red flag?
Likely yes — pricing guides flag quotes in the $2,000-$4,000 range as probable automated scans rather than manual tests, per DeepStrike.
Does the pentest cost include fixing the vulnerabilities it finds?
No. The quoted price covers testing and reporting; remediation work and the retest to confirm fixes worked are separate costs, with retesting commonly running 10-30% of the original fee (Startup Defense).
How often does a healthtech startup need to retest?
Industry convention is annually, plus a retest after any significant system change, even though HIPAA itself sets no fixed cadence (Accountable HQ).